VIP: Side Effects & Safety

VIP (Vasoactive Intestinal Peptide) is a 28-amino-acid endogenous neuropeptide first isolated by Said and Mutt in 1970.^[1] Your body produces it; it is widely distributed throughout the nervous system, gut, and immune cells. As an endogenous peptide given back at near-physiological concentrations, it has reasonable biological compatibility — most side effects are predictable amplifications of its normal physiology (vasodilation, intestinal secretion) rather than off-target toxicity.

The published clinical safety experience comes primarily from short-term IV studies in pulmonary hypertension and sarcoidosis research, and from compounded intranasal use in the Shoemaker CIRS (chronic inflammatory response syndrome) protocol. Formal Phase 2/3 trial data is limited.^[2]

VIP is not FDA-approved for any indication. It is not on the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee 503A bulks list agenda. It is currently available primarily through compounding pharmacies, often for the off-label Shoemaker protocol.

Effect	Frequency / Route	Notes
Nasal congestion / irritation	Common (intranasal)	Mild, transient; vasodilatory effect on nasal mucosa
Mild facial flushing	Common	Vasodilation; lasts 5–15 minutes post-dose
Hypotension (mild)	Occasional	Dose-dependent; symptomatic in volume-depleted or hypotensive patients
Diarrhea / loose stools	Occasional	VIP stimulates intestinal water and electrolyte secretion
Headache	Occasional	Vasodilation-related, usually transient
Mild tachycardia	Occasional	Reflex response to vasodilation
Bronchodilation	Mechanism-of-action, not adverse	VIP relaxes airway smooth muscle — generally desirable
Injection-site reaction	Mild (SC use)	Self-resolving
Allergic reaction	Rare	Discontinue immediately

No serious drug-related adverse events have been consistently reported in the published intranasal or short-term IV trials at typical research doses. Sample sizes remain small.

VIP is one of the body's most potent endogenous vasodilators. The clinical implications:

• Healthy normotensive adults: mild flushing and warmth post-dose, no clinically significant BP drop.
• Volume-depleted patients (dehydration, recent diuretic use): can produce symptomatic hypotension.
• Patients on antihypertensives (especially calcium channel blockers, ACE inhibitors, ARBs): additive BP reduction.
• Cardiovascular instability (heart failure, recent MI, arrhythmia): caution; vasodilation can worsen perfusion.

Practical rule: take BP and pulse at baseline. If systolic BP is < 100 mmHg or you have orthostatic symptoms, defer VIP use until volume status is adequate. Hydrate before dosing.

Important clinical context: VIPoma is a rare neuroendocrine tumor (pancreas, intestine) that secretes massive amounts of VIP. The clinical syndrome — severe watery diarrhea, hypokalemia, achlorhydria (WDHA / Verner-Morrison syndrome) — illustrates what extreme chronic VIP excess looks like.

Therapeutic VIP dosing produces nothing close to VIPoma-level exposure. Standard intranasal Shoemaker protocol doses (50 mcg per nostril, 4× daily) are far below the systemic exposure VIPoma patients experience. However, the syndrome is a reminder that VIP at sustained supraphysiological concentrations does produce real clinical consequences — secretory diarrhea, hypokalemia, dehydration — which is why most therapeutic protocols use intranasal short-half-life formulations rather than continuous infusion.

• Baseline hypotension or cardiovascular instability: avoid or use under medical supervision.
• Volume depletion / dehydration: hydrate first.
• Severe heart failure (NYHA III–IV): use caution; vasodilation may worsen perfusion.
• Recent myocardial infarction or arrhythmia: defer.
• Active diarrheal illness: additive secretory effect.
• Severe asthma or COPD: generally not contraindicated and may help (bronchodilator effect), but monitor; rare paradoxical bronchospasm has been reported.
• Pregnancy and breastfeeding: no controlled safety data; avoid.
• Active malignancy: VIP receptors are expressed on some tumors. Discuss with oncology.
• Known hypersensitivity to VIP or formulation excipients.

Drug interactions

• Antihypertensives (calcium channel blockers, ACE inhibitors, ARBs, alpha blockers, nitrates): additive BP-lowering effect. Monitor.
• PDE5 inhibitors (sildenafil, tadalafil): potential additive vasodilation. Space dosing.
• Beta blockers: may mask compensatory tachycardia from VIP-induced hypotension.
• Diuretics: volume depletion increases hypotension risk.
• Octreotide (somatostatin analog): opposing mechanisms — used to treat VIPoma syndrome.
• Alcohol: additive vasodilation; minimize.

• Nasal irritation: alternate nostrils, saline rinse before dosing.
• Dizziness / lightheadedness on standing: dose lying down for first few days; hydrate; reduce dose; check BP.
• Persistent diarrhea: reduce dose; ensure adequate hydration and electrolyte intake (especially potassium).
• Headache: hydrate; usually transient.
• Palpitations, chest discomfort: discontinue and seek cardiac evaluation.
• Severe diarrhea with weakness, muscle cramps (hypokalemia pattern): discontinue and seek medical evaluation; check electrolytes.
• Allergic reaction: discontinue immediately and seek emergency care.

See the VIP complete guide, dosage protocols, benefits and research, and the peptides for inflammation overview.